scholarly journals Cu(II) Benzoylpyridine Thiosemicarbazone Complexes: Inhibition of Human Topoisomerase II<i>α</i> and Activity against Breast Cancer Cells

2016 ◽  
Vol 06 (02) ◽  
pp. 146-154 ◽  
Author(s):  
Jennifer D. Conner ◽  
Wathsala Medawala ◽  
Madison T. Stephens ◽  
William H. Morris ◽  
Joseph E. Deweese ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Thiosemicarbazone Complexes

scholarly journals The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells

Oncotarget ◽  
2015 ◽  
Vol 6 (41) ◽  
pp. 43944-43963 ◽  
Author(s):  
Michelle S. Liberio ◽  
Martin C. Sadowski ◽  
Rohan A. Davis ◽  
Anja Rockstroh ◽  
Raj Vasireddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Natural Product ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Growth Arrest

scholarly journals Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells

PLoS ONE ◽  
2009 ◽  
Vol 4 (4) ◽  
pp. e5323 ◽  
Author(s):  
Justin Wray ◽  
Elizabeth A. Williamson ◽  
Melanie Royce ◽  
Montaser Shaheen ◽  
Brian D. Beck ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Topoisomerase Ii Inhibitors

scholarly journals PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells

2012 ◽  
Vol 84 (10) ◽  
pp. 1318-1331 ◽  
Author(s):  
Józefa Węsierska-Gądek ◽  
Nora Zulehner ◽  
Franziska Ferk ◽  
Andrzej Składanowski ◽  
Oxana Komina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cytotoxic Activity ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Selective Inhibitor ◽  
Parp Inhibition ◽  
Positive Breast Cancer

Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu

2008 ◽  
Vol 29 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Li Yen Shiu ◽  
Chia Hua Liang ◽  
Li Ching Chang ◽  
Hamm Ming Sheu ◽  
Eing Mei Tsai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Growth Factor Receptor ◽  
High Expression ◽  
Breast Cancer Patients ◽  
Expression Levels ◽  
Topoisomerase Ii Α

Trastuzumab is used for breast cancer patients with high expression levels of HER2 (human epidermal growth factor receptor 2)/neu; however, it has no effect on cancers with low levels of HER2/neu. SM (solamargine), a major steroidal alkaloid glycoside purified from Solanum incanum, triggered apoptosis of breast cancer cells (MCF-7 and SK-BR-3 cells) and non-cancerous breast epithelial cells (HBL-100 cells) within 3 h. To extend the application of trastuzumab in breast cancer patients, the regulation of HER2/neu expression by SM was investigated. SM significantly up-regulates HER2/neu expression in breast cancer cells with low and high expression levels of HER2/neu, and synergistically enhanced the effect of trastuzumab in inhibiting cell proliferation. Additionally, HER2/neu and TOP2A [TopoII (topoisomerase II) α] genes share the same amplicon on an identical chromosome. Notably, SM co-regulates HER2/neu and TopoIIα expression markedly, and enhances TopoII inhibitor–EPI (epirubicin)-induced cytotoxicity to breast cancer cells.

scholarly journals Phosphorylation and Stabilization of Topoisomerase IIα Protein by p38γ Mitogen-activated Protein Kinase Sensitize Breast Cancer Cells to Its Poisons

2011 ◽  
Vol 286 (41) ◽  
pp. 35883-35890 ◽  
Author(s):  
Xiaomei Qi ◽  
Songwang Hou ◽  
Adrienne Lepp ◽  
Rongshan Li ◽  
Zainab Basir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Topoisomerase Ii ◽  
Mitogen Activated Protein Kinase ◽  
Breast Cancers ◽  
New Paradigm ◽  
Cellular Targets ◽  
Mitogen Activated Protein ◽  
Topo Ii

Cancer drugs suppress tumor cell growth by inhibiting specific cellular targets. However, most drugs also activate several cellular nonspecific stress pathways, and the implications of these off-target effects are mostly unknown. Here, we report that p38γ, but not p38α, MAPK is specifically activated by treatment of breast cancer cells with topoisomerase II (Topo II) drugs, whereas paclitaxel (Taxol) does not have this effect. The activated p38γ in turn phosphorylates and stabilizes Topo IIα protein, and this enhances the growth inhibition by Topo II drugs. Moreover, p38γ activity was shown to be necessary and sufficient for Topo IIα expression, the drug-p38γ-Topo IIα axis is only detected in intrinsically sensitive but not resistant cells, and p38γ is co-overexpressed with Topo IIα protein in primary breast cancers. These results reveal a new paradigm in which p38γ actively regulates the drug-Topo IIα signal transduction, and this may be exploited to increase the therapeutic activity of Topo II drugs.

Sign in / Sign up

Export Citation Format

Share Document